GBIM:OTCMKTS
GlobeImmune Inc
0,00010 USD
0,00%
(0,00) 1 d.
29. 9., 15:48:52 GMT-4 · USD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre GBIM…
Trh. kap.
580,00
Priem. obj.
1,74 tis.
Objem
0,00
Max. za 52 týž.
0,04 USD
Min. za 52 týž.
0,00 USD
Akcie v obehu
5,75 mil.
Počet zamestnancov
22
Trh. kap.
580,00
Priem. obj.
1,74 tis.
Objem
0,00
Max. za 52 týž.
0,04 USD
Min. za 52 týž.
0,00 USD
Akcie v obehu
5,75 mil.
Počet zamestnancov
22
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
Yahoo Finance
·
pred 28 minútami
Sandisk Is Dominating the S&P 500 in 2026. Can It Repeat in 2027?
MarketBeat
·
pred 54 minútami
Turn Therapeutics (NASDAQ:TTRX) Cut to "Sell" at Wall Street Zen
MarketBeat
·
pred 1 hodinou
Amgen (NASDAQ:AMGN) Upgraded at Wall Street Zen
MarketWatch
·
pred 1 dňom
Don’t buy this dip: Several signs suggest there’s more pain ahead for tech stocks
Profil
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010.
As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia
Informácie o subjekte GlobeImmune Inc
Generálny riaditeľ-
Zamestnanci22
Dátum založenia1. 1. 1995
Hlavné sídloLouisville, Colorado, Spojené štáty americké
Odvetvie-